Royalty Pharma (RPRX) earnings

Earnings (net income) · fiscal 2025
$770.95M

Royalty Pharma (RPRX) reported net income of $770.95M in fiscal 2025 (the year ended December 31, 2025). That is 10.2% lower than the $858.98M of fiscal 2024. Figures as of 18 Nov 2026, 03:12 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Earnings (net income), fiscal 2025
$770.95M
Change on fiscal 2024
−10.2%
Growth, 5 years
−4.6% a year
Highest on record
$2.35Bfiscal 2019
Lowest on record
$42.83Mfiscal 2022
Fiscal years on record
82018–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Royalty Pharma earnings, in more detail

Over the five fiscal years to 2025 net income shrank at a compound 4.6% a year. Across the 8 fiscal years on record (2018–2025), the highest was $2.35B in fiscal 2019 and the lowest $42.83M in fiscal 2022.

History · 8 fiscal years

Earnings (net income) by fiscal year

Royalty Pharma earnings, year by year

Royalty Pharma (RPRX) earnings by fiscal year
Fiscal yearEarnings (net income)ChangeYear ended
2025$770.95M 10.2% down
2024$858.98M 24.3% down
2023$1.13B 2,549.5% up
2022$42.83M 93.1% down
2021$619.73M 36.4% down
2020$975.04M 58.5% down
2019$2.35B 70.5% up
2018$1.38B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

How to read it

Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.

Earnings (net income) at health care companies of similar size

Earnings (net income) of Royalty Pharma and comparable companies
CompanyEarnings (net income)Fiscal year
IQVIA Holdings IQV$1.36B2025
Revolution Medicines RVMD-$1.13B2025
Royalty Pharma RPRX$770.95M2025
Biogen BIIB$1.29B2025
GE HealthCare Technologies GEHC$2.08B2025
Alcon ALC$980.00M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on RPRX

Royalty Pharma, figure by figure

Royalty Pharma (RPRX) overview: price, valuation and scorecardAll health care companies by market value

Royalty Pharma earnings: questions and answers

What is Royalty Pharma's net income?

Royalty Pharma (RPRX) reported net income of $770.95M in fiscal 2025 (the year ended December 31, 2025). That is 10.2% lower than the $858.98M of fiscal 2024.

What is the growth rate of Royalty Pharma's net income?

Over the five fiscal years to 2025 net income shrank at a compound 4.6% a year.

What are the highest and lowest net income figures on record for Royalty Pharma?

Across the 8 fiscal years on record (2018–2025), the highest was $2.35B in fiscal 2019 and the lowest $42.83M in fiscal 2022.

How is Royalty Pharma's net income calculated?

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Royalty Pharma (RPRX) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/RPRX/earnings

Underlying data: the company's filings with the SEC and Yahoo Finance.